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Abstract
Aim: To determine whether biochemical parameters of cholinergic and oxidative stress function
including red cell acetylcholinesterase (AChE), serum⁄plasma thyroglobulin, selenium, iron, ferritin,
vitamins C, E, and A affect risk in apparent life-threatening event (ALTE), sudden infant death syndrome
(SIDS), and sudden unexpected death in infancy (SUDI). To assess these biochemical parameters as a
function of age; and for inﬂuence of pharmacology and epidemiology, including infant health, care, and
feeding practices.
Methods: A multicentre, case–control study with blood samples from 34 ALTE and 67 non-ALTE
(control) infants matched for age, and 30 SIDS⁄SUDI and four non-SIDS⁄non-SUDI (post-mortem
control) infants.
Results: Levels⁄activity of the biochemical parameters were not signiﬁcantly different in ALTE vs.
control infants, with the exception of higher vitamin C levels in the ALTE group (p = 0.009). In ALTE
and control groups, AChE and thyroglobulin levels increased and decreased respectively from birth to
attain normal adult levels from 6 months. Levels of iron and ferritin were higher in the ﬁrst 6 month
period for all infant groups studied, intersecting with vitamin C levels peaking around 4 months of age.
Conclusion: Lower AChE levels and higher combined levels of iron and vitamin C in the ﬁrst 6 months of life
may augment cholinergic and oxidative stress effect, particularly at the age when SIDS is most prevalent. This
may contribute to risk of ALTE and SIDS⁄SUDI events during infancy.
INTRODUCTION
A unifying mechanism for sudden infant death syndrome
(SIDS) remains elusive. It is widely accepted, however, that
SIDS infants have a vulnerable predisposition, exacerbated
by exogenous stressors, at a critical stage of development
(1). Against this background the sleep state, often with com-
promised sleep situation, appears to determine whether
SIDS is the outcome or not.
As a possible mechanism for SIDS, this study proposed
that increased cholinergic tone and oxidative stress contrib-
ute to vulnerability in SIDS infants, with vagally mediated
reﬂexes and oxidative stressors exacerbating this vulnerabil-
ity, most critically in a sleep state affected by hypoxia.
The rationale for this mechanism, and the biochemical
parameters examined, reﬂect known epidemiological, clini-
cal, and pathological features of the syndrome. Cholinergic
transmission, acting centrally; and peripherally at auto-
nomic ganglia, parasympathetic effector organs, and neuro-
muscular junctions; can be increased directly (receptor
agonists), through mimicking of the acetylcholine neuro-
transmitter e.g. nicotine, or indirectly by inhibiting the
enzyme acetylcholinesterase (AChE), which degrades
the neurotransmitter (2). Increased cholinergic activity
producing mucus secretion, sweating, vomiting, sphincter
relaxation, airway obstruction, bradycardia, and initial mus-
cle tonicity followed by more prolonged ﬂaccidity, has been
commonly reported in apparent life-threatening event
(ALTE) infants, and SIDS infants prior to their deaths (3,4).
Reactive oxygen species or free radicals are constantly
produced in the body, with protection of body tissues from
oxidative stress conferred by antioxidants (5). Intermittent
hypoxia then reoxygenation, as experienced premorbidly by
some SIDS infants, and oxidation of catecholamines
produced in response to stress, can generate superoxide free
radicals (6). While superoxide itself is relatively unreactive,
it acts as a precursor for more reactive species with its
conversion to hydrogen peroxide, which in turn may be
converted in the presence of transition metal ions e.g. Cu
+
and Fe
++ (vitamin C acting as an oxidant reducing Fe
+++ to
Fe
++) to the most reactive and damaging of the oxygen free
radicals, the hydroxyl (Fenton reaction) (5,6).
One of the intracellular targets for the hydroxyl radical is
the phospholipid component of membranes resulting in
lipid peroxidation and membrane disruption (5). In the
blood vessels and mucosa of the respiratory tract, lipid per-
oxidation combined with oxidative release of inﬂammatory
mediators (7) and vagally mediated neurogenic inﬂamma-
tion (8), may produce the intrathoracic petechiae,
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trate often seen in SIDS victims (9).
Vitamin E, as alpha-tocopherol, acts as a chain breaking
antioxidant in lipid peroxidation intercepting lipid peroxyl
radicals. Vitamin C reacts with the tocopherol radical pro-
duced to reconvert it to alpha-tocopherol, thereby acting as
an antioxidant in the absence of transition metal ions rather
than an oxidant (5).
The provitamin A carotenoid beta-carotene is also a scav-
enger of peroxyl radicals. This activity may be increased in
the presence of other antioxidants, e.g. vitamin E, but pro-
oxidant activity has been reported when taken in high dose
and in the presence of highly oxidative conditions (10).
Selenium is involved in oxidative protection as an essen-
tial component of glutathione peroxidase, which safely
reduces hydrogen peroxide and other organic hydroperox-
ides (5,6).
A possible relationship between AChE and thyroglobulin
[precursor of triiodothyronine (T3) and tetraiodothyronine
(T4) thyroid hormones], is reﬂected in their shared homolo-
gies, immunoreactivity, and oxidative chemistry. The
Fenton chemistry, which cleaves thyroglobulin within its
cholinesterase-like-domain into immunoreactive, T3, T4
hormone producing peptides (11), has also been shown to
cleave and deactivate AChE (12).
The aims of this study were therefore: (i) to assess if activ-
ity of AChE, reﬂecting the enzyme AChE that inactivates
acetylcholine in the cholinergic nervous system, was low in
ALTE, SIDS, and sudden unexpected death in infancy
(SUDI) infants; (ii) to evaluate thyroglobulin for reciprocal
inverse response with AChE; (iii) to assess if decreased oxi-
dative stress protection, as determined by low levels of an-
tioxidants selenium, vitamin E, ± vitamin A, high levels of
pro-oxidants iron and ferritin, and conditional pro-oxidant
effect of vitamin C, was present in ALTE and SIDS⁄SUDI
infants; (iv) to measure levels⁄activity of these biochemical
factors as a function of age to determine if they confer inﬂu-
ence on the age of risk for SIDS; and (v) to examine the
inﬂuence of pharmacology and epidemiology, including
infant health, care, and feeding practices, on these biochem-
ical factors.
METHODS
This multicentre, case–control study was conducted in New
Zealand, at Auckland, Wellington, Christchurch, and Dun-
edin hospitals, over a 10-year period between 1996 and
2006. After obtaining informed consent from parents or
guardians, blood samples of up to 3.5 mL were collected
from ALTE and non-ALTE (control) infants, and SIDS⁄
SUDI and non-SIDS⁄non-SUDI (post-mortem control)
infants. Attempt was made to perform all biochemical
assays on samples collected, i.e. AChE, also measured per
gram haemoglobin (AChE⁄gHb) recognizing changing red
cell mass with infant age, serum⁄plasma thyroglobulin, sele-
nium, iron, ferritin, and vitamins C, E, and A.
Blood samples from ALTE and control infants matched
for age, two for each case, were obtained between 1996 and
2006 at Christchurch Hospital. The additional blood sample
was taken at the time of blood sampling for other reasons,
in the medical management of these infants. Inclusion crite-
ria for ALTE infants were a frightening event, between
1 week and 1 year of age, characterized by at least two out
of three of the following: (i) apnoea (central or occasionally
obstructive), choking or gagging; (ii) colour change (usually
cyanotic or pallid, but occasionally erythematous or pletho-
ric); and (iii) marked change in muscle tone (usually
marked limpness) (13). Infants were excluded from ALTE
and control groups if tonic-clonic seizure was a feature of
their presentation.
Blood samples were collected from the superior vena
cava for SIDS⁄SUDI and post-mortem control infants pre-
senting for post-mortem between 1996 and 2006. All
SIDS⁄SUDI samples were collected at Christchurch Hospi-
tal. With only small numbers of non-SIDS⁄non-SUDI
infants presenting, local ethics approval was sought to
extend the study to hospitals in Dunedin in 1996, and Auck-
land and Wellington in 1997, for the post-mortem collec-
tion of control samples. In this study, the 1969 deﬁnition of
SIDS was used: ‘the sudden death of an infant or young
child, which is unexpected by history, and in which a
thorough post-mortem examination fails to demonstrate an
adequate cause for death’ (9). From 1998, an upper limit of
1 year was set in accordance with local practices for SIDS
classiﬁcation. For the purposes of this study, infants under
1 year satisfying the 1969 SIDS deﬁnition were classiﬁed as
SIDS, and a classiﬁcation of SUDI was given to infants with
similarly unexplained deaths aged between 1 and 2 years.
Causes of death and their classiﬁcation were reviewed
by the pathologist who conducted the majority of post-
mortems over the study period.
To examine the inﬂuence of pharmacology and epidemi-
ology on these biochemical factors, a questionnaire was
completed with reference to obstetric, medical, and nursing
records of the infant.
Blood samples were analysed by Canterbury Health Lab-
oratories, the Free Radical Research Group (University of
Otago), and LabPlus Auckland. Over the course of the
study, assay methods changed, but correlation assays con-
ﬁrmed no signiﬁcant effect on the consistency of measure-
ment. Changes in method standardization for the AChE
assay, however, did affect reported results. To ensure consis-
tent measurement, adjusted AChE and AChE⁄gHb levels
were used, calculated from results for all AChE assays per-
formed at the laboratory during the study period. There
were also concerns over the validity of vitamin C assays
reported from two batches and these were excluded from
analyses.
Assay methods for this study included the following.
For AChE, a colorimetric determination was performed
using the 5,5-dithiobis-2-nitrobenzoate (DTNB) method
for the Cobas Bio analyser (Roche Diagnostics, Indianapo-
lis, IN, USA). Haemoglobin measurement for AChE⁄gHb
was performed using Coulter technology, a Coulter STKS
analyser (Coulter, Hialeah, FL, USA) until 1999, and a
Coulter GenS analyser (Coulter Corp., Miami, FL, USA),
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Sorin (Sorin Biomedica Diagnostics S.p.A., Saluggia, Italy)
immunoradiometric (IRMA) method until the end of
October 2002, an automated method using the Immulite
analyser (Siemens, Tarrytown, NY, USA) from November
2002, and a chemiluminescent immunoenzymatic assay on
the Access analyser (Beckman Coulter Inc., Fullerton, CA,
USA) from May 2003. Plasma selenium was measured by
graphite furnace atomic absorption spectroscopy using
pyrolytically coated graphite partition tubes and Zeeman
background on a Varian 220Z analyser (Varian Inc.,
Mulgrave, Australia). The iron assay was performed using
photometric measurement, initially with Roche reagents
(Roche Diagnostics GmbH, Mannheim, Germany) on the
Hitachi 717 (Roche Diagnostics), and later with Sentinel
reagents (Sentinel Diagnostics, Milan, Italy) on the Abbott
Aeroset and Abbott Architect c8000 analysers (Abbott
Laboratories, Abbott Part, IL, USA). The IMX ferritin
assay (Abbott Laboratories), based on the microparticle
enzyme immunoassay (MEIA) technology, was used until
the end of April 2005, and was then replaced with the
Architect ferritin assay (Abbott Laboratories), a chemilu-
minescent microparticle immunoassay (CMIA). Plasma
vitamin C was measured by high performance liquid chro-
matography (HPLC) using a C18 column (Phenomenex,
San Jose, CA, USA) with electrochemical detection. Vita-
mins E and A were similarly measured by HPLC using a
C18 column (Phenomenex) with ultraviolet detection.
The statistical analysis system (SAS) version 9.1 (SAS
Institute Inc., Cary, NC, USA) was used for statistical analy-
sis. ALTE and control groups were analysed using t-tests for
paired samples. Biochemical parameters for each ALTE
infant were compared with mean biochemical parameters
from available controls for that infant. Correlations and par-
tial correlations were used to analyse the relationships
between AChE, AChE⁄gHb, thyroglobulin, and age; analy-
sis of variance (ANOVA) and analysis of simple effects, the
relationship between smoking and thyroglobulin levels. To
examine the relationships between iron⁄ferritin levels,
infant age, and method of feeding, regression analysis was
carried out to decide terms for age in the model, with
breast-fed and formula-fed infants compared using ANO-
VA. The frequency of maternal iron supplementation and
inﬂuence on iron⁄ferritin levels in the infant groups were
examined using chi-square and pooled t-tests respectively.
Logarithmic transformation was used as necessary to man-
age skewed data and large values for thyroglobulin, iron,
ferritin, and vitamin C parameters.
Ethical approval for this study was obtained from the
Canterbury Ethics Committee⁄Upper South Regional Eth-
ics Committees, and the local ethics committees of other
participating sites.
RESULTS
Blood samples were collected from 37 ALTE infants and 69
control cases. Three infants under 1 week of age were
excluded from the ALTE group, and two infants presenting
with tonic-clonic seizure from the control group, leaving 34
ALTE infants and 67 control infants in the study. The ﬁve
infants excluded from these groups were categorized as
‘infant other’.
Post-mortem blood samples were collected from 28 SIDS
infants, two SUDI, and four post-mortem control infants
between 1996 and 2006. Causes of death for the four post-
mortem control infants were drowning, accidental asphyxia,
smoke and fume inhalation, and cerebral infarction during
cardiac surgery.
A comparison of biochemical parameter means for the
ALTE and control groups is shown in Table 1. The only sig-
niﬁcant difference identiﬁed was higher vitamin C levels in
the ALTE group (p = 0.009).
The small number of post-mortem control infants avail-
able to this study prevented case–control analysis of SIDS⁄
SUDI infant biochemistry. Table 2 presents a summary of
data for post-mortem infant groups.
Further examination of individual biochemical parame-
ters showed AChE and AChE⁄gHb to be highly correlated
statistically (0.88), increasing with age 0.59⁄0.59 to achieve
normal adult levels by 6 months of age for ALTE and con-
trol infants (Fig. 1a). Mean levels in the SIDS⁄SUDI infants
(Table 2) were slightly lower than other infant groups,
however the small numbers of post-mortem control infants
and age disparity did not allow for statistical analysis.
Thyroglobulin levels reduced from birth to attain normal
adult levels by 6 months of age for ALTE and control
Table 1 Comparison of biochemical parameter means for ALTE and control infants
Parameters n ALTE mean (SD) Control mean (SD) Mean diff (SD) 95% CI p-value
AChE (KU⁄L) 30 8.8 (2.2) 9.2 (2.0) )0.4 (2.2) )1.2 to 0.4 0.35
AChE (U⁄gHb) 22 34.0 (8.0) 35.8 (6.8) )1.8 (8.4) )5.5 to 1.9 0.32
Thyroglobulin (mcg⁄L) 27 44.7 (25.3) 40.5 (24.2) 4.2 (38.0) )10.8 to 19.3 0.57
Selenium (mcmol⁄L) 30 0.45 (0.17) 0.47 (0.23) )0.02 (0.35) )0.15 to 0.11 0.71
Iron (mcmol⁄L) 28 10.6 (4.1) 10.8 (6.8) )0.2 (6.5) )2.8 to 2.3 0.84
Ferritin (mcg⁄L) 31 139.8 (96.8) 159.4 (109.0) )19.6 (97.7) )55.4 to 16.3 0.27
Vitamin C (mcmol⁄L) 19 81.8 (23.8) 63.3 (26.6) 18.5 (27.4) 5.3 to 31.8 0.009
Vitamin E (mcmol⁄L) 30 23.5 (9.6) 23.4 (10.0) 0.1 (16.0) )5.9 to 6.1 0.97
Vitamin A (mcg⁄L) 30 295.9 (132.5) 261.6 (97.5) 34.2 (140.0) )18.0 to 86.5 0.19
n = number of ALTE infants with at least one control infant; ALTE = apparent life-threatening event; AChE = red cell acetylcholinesterase; Hb = haemoglobin;
SD = standard deviation; diff = difference; CI = conﬁdence interval.
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AChE levels to be negatively correlated with thyroglobulin
()0.23) which in turn declined with age ()0.41). Partialling
out the effect of age, there was no correlation remaining
between AChE and thyroglobulin ()0.07). In SIDS⁄SUDI
and most post-mortem control infants, levels were elevated
with no apparent relationship to age or AChE levels. We
have previously shown higher thyroglobulin levels in cord
blood samples where there was maternal smoking (A. Dick
and R. Ford, unpubl. data), with analysis of maternal smok-
ing⁄non-smoking during pregnancy showing signiﬁcant
interaction of thyroglobulin with smoking (p = 0.01). The
same interaction of thyroglobulin with maternal smoking
during pregnancy (closely correlated with postnatal rate of
smoking) did not extend postnatally to ALTE⁄control
infants examined in this study (p = 0.15).
Mean selenium levels remained low normal or below nor-
mal adult levels throughout the ﬁrst year (Tables 1 and 2).
Method of feeding was not observed to affect selenium lev-
els overall, however the highest levels of >1.0 mcmol⁄L
were reported in infants on formula feeds ± solids.
Iron levels in ALTE and control infants reduced from
birth to low normal adult levels from 6 months, remaining
at that level during the ﬁrst year of life (Fig. 1c). Mean iron
levels in SIDS infants were elevated, peaking at 18 weeks
with a level of >750 mcmol⁄L (given as 750 mcmol⁄L for
the purposes of statistical analyses, graphs, and tables), and
reducing subsequently (Fig. 1d). In ALTE and control
infants, iron levels appeared to be higher in breast-fed
infants, but statistical analysis comparing ‘mainly breast-
fed’ and ‘mainly formula-fed’ infants (post-mortem groups
and infants on solids excluded) showed this to be related to
the younger age of breast-fed infants and not method of
feeding (p = 0.57). Maternal iron supplementation during
pregnancy (not inclusive of low-dose iron from multivita-
min and mineral supplementation) was signiﬁcantly higher
in mothers of SIDS infants when compared with mothers of
ALTE (p = 0.04) and control infants (p = 0.03). Anaemia of
pregnancy was not over-represented in mothers of SIDS
infants with four mothers from the ALTE group, ﬁve from
the control group, and three from the SIDS group receiving
iron supplementation for antenatal haemoglobins of
<100 g⁄L. In the small numbers examined, higher mean
iron levels were reported in SIDS infants (infants on iron
supplementation excluded) where maternal iron supple-
mentation occurred during pregnancy, 104 mcmol⁄L
(n = 18) compared with 45 mcmol⁄L (n = 7) where no
maternal iron supplementation took place. This approached
Table 2 Post-mortem infant group data for biochemical parameters
Parameter Infant group n
Mean age
(weeks) Mean value Median value Range Reference range
AChE (KU⁄L) SIDS 28 15.3 8.0 7.8 5.1–10.8 >8
SUDI 2 80.9 6.6 6.6 5.2–7.9
P-m control 3 62.1 9.4 9.8 8.5–9.9
AChE⁄gHb (U⁄gHb) SIDS 27 15.5 29.9 30.0 18.8–45.7 30–51*
SUDI 2 80.9 21.7 21.7 17.6–25.7
P-m control 2 71.4 35.9 35.9 34.6–37.1
Thyroglobulin (mcg⁄L) SIDS 27 15.7 1004.4 358.0 34.0–5260.0 0–58
SUDI 2 80.9 2037.5 2037.5 71.0–4004.0
P-m control 4 52.6 168.3 123.0 35.0–392.0
Selenium (mcmol⁄L) SIDS 27 14.6 0.48 0.45 0.11–1.08 0.45–1.40
SUDI 2 80.9 1.02 1.02 0.64–1.39
P-m control 2 71.4 0.42 0.42 0.39–0.44
Iron (mcmol⁄L) SIDS 26 14.6 85.0 45.0 20.0–750.0 10–30
SUDI 2 80.9 22.0 22.0 14.0–30.0
P-m control 2 71.4 17.5 17.5 11.0–24.0
Ferritin (mcg⁄L) SIDS 21 15.7 39455.7 21384.0 695.0–99000.0 15–150
SUDI 2 80.9 1337.5 1337.5 1119.0–1556.0 (0–14 years)
P-m control 2 71.4 1216.0 1216.0 1030.0–1402.0
Vitamin C (mcmol⁄L) SIDS 20 15.0 218.5 223.3 6.9–649.4 26–85
SUDI 1 88.7 411.5 411.5
P-m control 1 90.9 95.2 95.2
Vitamin E (mcmol⁄L) SIDS 24 15.2 27.6 23.0 3.0–65.0 23–70
SUDI 1 88.7 21.0 21.0 (rec level)
P-m control 3 62.1 19.3 20.0 17.0–21.0
Vitamin A (mcg⁄L) SIDS 24 15.2 344.5 339.5 88.0–634.0 200–800
SUDI 1 88.7 308.0 308.0 (rec level)
P-m control 3 62.1 376.7 253.0 183.0–694.0
Reference ranges provided by Canterbury Health Laboratories unless otherwise indicated.
AChE = red cell acetylcholinesterase; Hb = haemoglobin; SIDS = sudden infant death syndrome; SUDI = sudden unexpected death in infancy; P-m =
post-mortem; rec = recommended.
*Sanz et al. (14).
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with iron supplementation during pregnancy in other
groups.
Ferritin levels increased in the ﬁrst 8 weeks of life for
ALTE and control infants, reducing to normal childhood
levels from 6 months of age (Fig. 1e). In SIDS, SUDI, and
post-mortem control infants, ferritin levels were elevated
(Table 2), particularly in the SIDS group where levels ran-
ged from 695 to >99 000 mcg⁄L (given as 99 000 mcg⁄L for
the purposes of statistical analyses and tables). Six other fer-
ritin levels, which either exceeded the upper limit for the
assay at the time (reduced from >99 000 to >40 000 mcg⁄L
in 2005), or where there was insufﬁcient sample after
repeated dilution to achieve a result, were excluded from
analyses. Higher ferritin levels were also seen in breast-fed
ALTE and control infants, analysis again showing this to be
related to the younger age of breast-fed infants, with a
non-signiﬁcant trend for lower ferritin in the ‘mainly for-
mula-fed’ group (p = 0.11). There was no statistical associa-
tion observed between maternal iron supplementation
during pregnancy and infant ferritin levels, although
reduced ferritin data in the SIDS group may have compro-
mised this analysis. Infant iron supplementation (by pre-
scription only for infants in this study) did not appear to
inﬂuence iron or ferritin levels for these particular infants.
Vitamin C levels for ALTE and control infants tended to
be low normal adult levels in the ﬁrst 3 weeks of life,
increasing to maximal levels around 4 months of age, and
(b) (a)
0
2
4
6
8
10
12
14
16
0
Age (weeks)
A
C
h
E
 
(
K
U
/
L
) ALTE
Control
Infant other
SIDS
SUDI
P-m control
0
20
40
60
80
100
120
140
0
Age (weeks)
T
h
y
r
o
g
l
o
b
u
l
i
n
 
(
m
c
g
/
L
)
ALTE
Control
Infant other
(d) (c)
0
5
10
15
20
25
30
Age (weeks)
I
r
o
n
 
(
m
c
m
o
l
/
L
)
ALTE
Control
Infant other
0
100
200
300
400
500
600
700
800
Age (weeks)
I
r
o
n
 
(
m
c
m
o
l
/
L
)
SIDS
SUDI
P-m control
(f) (e)
0
50
100
150
200
250
300
350
400
450
Age (weeks)
F
e
r
r
i
t
i
n
 
(
m
c
g
/
L
)
ALTE
Control
Infant other
0
100
200
300
400
500
600
700
Age (weeks)
V
i
t
a
m
i
n
 
C
 
(
m
c
m
o
l
/
L
)
ALTE
Control
Infant other
SIDS
SUDI
P-m control
100 80 60 40 20
0 100 80 60 40 20
0 100 80 60 40 20
60 50 40 30 20 10
0 60 50 40 30 20 10
0 60 50 40 30 20 10
Figure 1 Level of biochemical parameters (a) red cell acetylcholinesterase (normal range >8); (b) thyroglobulin (reference range 0–58 mcg⁄L); (c) iron (reference
range 10–30 mcmol⁄L); (d) iron post-mortem; (e) ferritin (reference range for 0–14 years, 15–150 mcg⁄L); (f) vitamin C (reference range 26–85 mcmol⁄L); as
a function of age. Reference ranges provided by Canterbury Health Laboratories. AChE = red cell acetylcholinesterase; ALTE = apparent life-threatening event;
SIDS = sudden infant death syndrome; SUDI = sudden unexpected death in infancy; P-m = post-mortem.
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(Fig. 1f). Levels between 6 and 30 weeks of age often
exceeded the adult upper limit for vitamin C, particularly in
SIDS infants, although very low levels of <10 mcmol⁄L
were also reported in two SIDS infants.
For all the infant groups, mean vitamin E and A levels
remained low or low normal when compared with recom-
mended levels, over the ﬁrst 2 years of life (Tables 1 and 2),
with addition of solids appearing to increase vitamin A lev-
els slightly.
There were trends for maternal supplementation during
pregnancy with vitamins C, E, and A to increase reported
levels of those vitamins in SIDS infants, and for infant sup-
plementation with Vitadol C (Nutricia Ltd, Auckland, New
Zealand) (daily dose: vitamin A 666.7 mcg, vitamin C
33.3 mg, vitamin D 11.7 mcg) to increase vitamin C levels
in supplemented infants, although numbers were too small
for statistical analyses. Maternal supplementing with iron
and vitamins while breast feeding, was not shown to inﬂu-
ence infant levels in any of the groups studied.
When pharmacological factors were analysed, levels of
exposure to maternal smoking, alcohol, recreational drug
use (e.g. marijuana, benzodiazepines), methadone, and caf-
feine consumption were comparable in ALTE and control
groups, but at least twice the level of exposure was observed
in SIDS infants compared with other groups. Use of these
substances did not appear to affect the biochemical parame-
ters studied in this study.
Opiates in some form (morphine, pholcodine, and herbal
withania root) were more commonly administered in SIDS
infants (14%). Infant use of these opiates, again, did not
appear to inﬂuence the biochemical parameters studied,
nor did maternal or infant use of any other medications
examined in this study.
All SIDS and SUDI deaths occurred during assumed
sleep, with 59% of ALTE infants also thought to be sleeping
at the time of their events. Compromised sleep situation dis-
tinguished the SIDS⁄SUDI group from the ALTE group.
When infant health was examined, gastro-oesophageal
reﬂux (GOR) was more prevalent among ALTE infants
(56%), and upper respiratory symptoms among SIDS⁄SUDI
infants (53%), although ﬁve further SIDS infants experi-
enced spilling and unexplained irritability, which may have
represented undiagnosed GOR.
No trends were observed in levels of biochemical parame-
ters as a result of sleep situation, underbedding (with spe-
ciﬁc reference to acetycholinesterase levels), ethnicity
(Maori vs. non-Maori), or the health conditions examined.
DISCUSSION
We have hypothesized that increased cholinergic tone and
oxidative stress contribute to an increased risk of SIDS
examining parameters of cholinergic and oxidative stress
function.
Assessing the aims of this study, we have observed that
mean AChE levels were slightly lower in the SIDS⁄SUDI
infants compared with other infant groups, but have shown
no statistical difference in AChE levels between ALTE and
control infants. While thyroglobulin showed a reciprocal
inverse relationship with AChE in ALTE and control
infants, this was conﬁrmed statistically to be a function of
age with no direct correlation between AChE and thyro-
globulin levels. Pro-oxidant parameters, iron and ferritin
were elevated in SIDS infants, with ferritin levels in SUDI
infants elevated to a lesser degree, comparable to levels in
post-mortem control infants. Vitamin C with antioxidant
properties, but also pro-oxidant activity in the presence of
iron (5,6), similarly showed elevated levels in most SIDS⁄
SUDI infants with statistically signiﬁcant increased levels in
ALTE when compared with control infants. Mean levels of
antioxidants selenium (5,6) and vitamin E (5,6), and vitamin
A (with variably reported oxidative effect) (10), were gener-
ally low or low normal across all groups compared with
adult or recommended levels. When assay levels of these
parameters were examined as a function of age, AChE and
thyroglobulin in ALTE and control infants increased and
decreased respectively over the ﬁrst 6 months to attain nor-
mal adult levels thereafter. Higher levels of iron and ferritin
over the ﬁrst 6 months of life intersected with vitamin C lev-
els, at their height around 4 months of age. There were
trends for maternal iron and vitamin supplementation dur-
ing pregnancy to increase reported levels of these parame-
ters in SIDS infants, and for infant vitamin supplementation
using Vitadol C to increase vitamin C levels in supple-
mented infants. Higher levels of smoking and recreational
drug use in mothers of SIDS infants, opioid use within the
SIDS group, and compromised sleep situation, did not
appear to inﬂuence these biochemical parameters per se,
but may have contributed to cholinergic, hypoxic, and oxi-
dative stress mechanisms. Likewise GOR and upper respira-
tory symptoms, more prevalent in ALTE and SIDS infants,
showed no apparent relationship with levels of biochemical
parameters, although a cholinergic effect through vagal
reﬂexes was possible (15).
Our results support the hypothesis that increased cholin-
ergic tone and oxidative stress effect contribute to the vul-
nerability of SIDS infants and their age of risk. Exogenous
stressors, as discussed, may disturb homeostatic balance
when oxidative stress overwhelms antioxidant protection,
e.g. with maternal smoking, hypoxia; when cholinergic
transmission is increased per AChE inhibition⁄nicotine
stimulation prior to receptor down-regulation [observed
with muscarinic receptors (16), although conversely,
nicotinic receptors may be up-regulated by nicotine (17)];
during transitions in cholinergic modulation of central
respiratory control as a consequence of previous opioid
exposure (18), reduced activity of the central muscarinic
receptors responsive to hypercapnia and asphyxia (19), or
AChE action, direct⁄indirect, on hydrolysis of opposing
respiratory neuropeptides, e.g. substance P (20,21), enkeph-
alin (22); and with mediation of vagal trigger reﬂexes, e.g.
the laryngeal chemoreﬂex (LCR). The LCR can produce
apnoea, laryngeal constriction or closure, and bradycardia,
per liquid stimulus to the laryngeal mucosa (15,23). Micro-
aspiration of gastric ﬂuid, laryngeal inﬂammation, and
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act as a trigger mechanism in ALTE and SIDS⁄SUDI infants
per the higher rates of GOR, respiratory syncytial virus
infection, upper respiratory tract infection⁄mucus secretion,
seen in these infants. The LCR can be further augmented
during hypoxia (15), with the use of cholinergic agents (23),
and possibly during non-rapid eye movement sleep, when
parasympathetic outﬂow increases and sympathetic outﬂow
decreases (24), reducing opportunity for sympathetic pres-
sor response.
There have been few studies examining these parameters
in the context of SIDS. Higher concentrations of blood and
serum ferritin were previously reported in SIDS infants
compared with post-mortem controls, although this was
thought to be characteristic of infant age rather than SIDS
speciﬁcally (25). A Scandinavian study found an association
between increased risk of SIDS and infants not given vita-
min A supplementation during the ﬁrst year of life (26). In
other infant studies, higher vitamin C levels in the ﬁrst few
days of life have been associated with an increased risk of
dying in very preterm infants (27), and higher thyroglobulin
levels in cord blood were observed with combined mater-
nal⁄paternal smoking during pregnancy, high levels persist-
ing for at least a year, if exposure to passive smoking from
both parents was continued (28).
It should be acknowledged that this study lacked sufﬁ-
cient power to draw conclusions about maternal and infant
supplementation. The fact, however, that vitamin C can be
actively transported across the placenta (29), and oral iron
transfer to the foetus up-regulated in women with depleted
iron stores (30), suggests that maternal supplementation in
pregnancy holds relevance for the foetus and potentially the
infant.
Local practice has seen a reduction in iron prophylaxis
for pregnant women and an increasing use of over the coun-
ter multivitamin preparations. Iron and vitamin supplemen-
tation in infants is usually by medical prescription and
restricted to low birth weight and premature infants. For
these infants, initial vitamin supplementation with Vitadol
C and Micelle E (Natural Bio Pty Ltd., Warriewood, Austra-
lia) (d-alpha-tocopheryl acetate) may be commenced soon
after birth with additional iron supplementation at 4–
6 weeks (if not on formula), combined iron and Vitadol C
continued thereafter until solids are established (around
6 months corrected).
Our capacity, in this study, to assess the SIDS biochemis-
try and effect of post-mortem artefact, was also limited given
the paucity of post-mortem control data. Ferritin is rapidly
released into the blood post-mortem (25), and it is possible
that the very high vitamin C levels in SIDS⁄SUDI infants
are simply a marker of signiﬁcant cerebral insult and release
of the vitamin from ascorbate-rich brain tissue (27).
Sudden infant death syndrome nevertheless occurs when
tissue iron levels are higher than at any other time because
of the high rate of haemoglobin breakdown and relatively
low rate of synthesis (25). At 6–20 weeks of age, when risk
for SIDS is greatest, high levels of vitamin C potentially
interact with high levels of iron, to exacerbate oxidative
stress at a time when low levels of selenium and vitamins E
and A compromise antioxidant protection. Reduced smok-
ing exposure, and safe sleeping practices may have curbed
some cholinergic and oxidative stress effect and decreased
SIDS risk accordingly. Further investigation is needed to
evaluate best practice for supplementation, in particular
with iron and vitamin C, during pregnancy and the ﬁrst
6 months of life.
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